|3.||Hepatocellular Carcinoma (Hepatoma)
|5.||Chronic Hepatitis B
|1.||Trautwein, Christian: 53 articles (11/2015 - 04/2002)|
|2.||Manns, Michael P: 53 articles (08/2015 - 06/2002)|
|3.||Younossi, Zobair M: 48 articles (12/2015 - 09/2002)|
|4.||Lindor, Keith D: 40 articles (01/2016 - 02/2002)|
|5.||Tacke, Frank: 38 articles (11/2015 - 04/2002)|
|6.||Nobili, Valerio: 37 articles (01/2016 - 11/2004)|
|7.||Trauner, Michael: 36 articles (12/2015 - 05/2002)|
|8.||Mieli-Vergani, Giorgina: 33 articles (02/2016 - 01/2002)|
|9.||Vergani, Diego: 29 articles (02/2016 - 01/2002)|
|10.||Sanyal, Arun J: 29 articles (09/2015 - 09/2003)|
|1.||Ursodeoxycholic Acid (Urso)FDA LinkGeneric
02/01/1994 - "Ursodeoxycholic acid has been reported to be beneficial for patients with various chronic cholestatic liver diseases. "
01/01/1994 - "Ursodeoxycholic acid (UDCA) is clinically beneficial in chronic cholestatic liver disease, but the underlying mechanisms are unclear. "
07/01/2012 - "Ursodeoxycholic acid (UDCA) is widely used for the treatment of liver dysfunction. "
02/01/2004 - "Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. "
02/01/2004 - "Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease."
01/01/2001 - "The short courses of interferon monotherapy that were used in the early 1990s led to sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of patients. "
02/01/2000 - "Interferon monotherapy became clinically available 10 years ago but resulted in sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of treated patients. "
11/01/1995 - "Thus, longterm interferon treatment seems effective in clearing hepatitis C virus from serum of patients with chronic liver disease."
01/01/1990 - "These results indicate that interferon is effective in inducing clearance of HBV from serum and improvement of biochemical and histological parameters of liver disease. "
09/01/2003 - "In the absence of suitable animal models, HCV dynamic studies in man have been helpful in defining the mechanisms of action of interferon in chronic HCV liver disease. "
|3.||Hepatitis B e AntigensIBA
10/01/2012 - "In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease."
01/01/1995 - "We now show that the number of amino acid substitutions in the HBV core is low in viral sequences from patients with HBeAg positive chronic liver disease and HBeAg negative HBeAb positive patients in remission, but the frequency of substitutions is high in HBeAg, negative HBeAb positive patients with active liver disease. "
09/01/2006 - "Courses of finite duration, aiming to achieve sustained off-therapy responses, are practically restricted to HBeAg+ patients with compensated chronic liver disease, whereas long-term therapy aiming to achieve maintained on-therapy remission is mostly applicable to HBeAg- individuals either with early or advanced liver disease. "
07/01/1996 - "Conversely about 90% of children infected later in life clear HBeAg and achieve sustained remission of liver disease before reaching adulthood. "
03/01/2007 - "These will be followed eventually by HBeAg seroconversion, which is usually accompanied by remission of liver disease and confers favourable outcome. "
|4.||Lamivudine (3TC)FDA Link
08/01/2000 - "A significant reduction was noted in the morbidity and hospitalizations for complications of liver disease before and after starting lamivudine (1.5+/-0.7 vs. 0.6+/-0.7, p<0.002). "
07/01/2000 - "Liver disease-significant improvement with lamivudine."
11/01/2002 - "Lamivudine has previously been found to be effective not only in patients with compensated liver disease due to hepatitis B virus (HBV) but also in those with hepatic decompensation. "
01/01/2008 - "However, liver dysfunction was not improved by lamivudine. "
06/20/2014 - "Criteria adopted for starting lamivudine were the 2001 American Association for the Study of Liver Diseases guidelines. "
|5.||DNA (Deoxyribonucleic Acid)IBA
05/01/1997 - "The results show that in general, the branched DNA assay detects HBV DNA in more patients than hybrid-capture and that this improved detection rate is relevant clinically and genome equivalents/ml are preferred to pg/ml to quantify HBV DNA in clinical specimens and finally qualitative, non-quantitative polymerase chain reaction can detect HBV DNA in patients without evidence of active HBV-related liver disease. "
07/01/2000 - "No TTV infected child [follow-up: 31 (median; range: 6-60) months] showed signs of liver disease; five infants cleared TTV DNA after 22 (median; range: 6-60) months. "
04/01/1999 - "Advances in computer-aided diagnosis, imaging techniques, DNA mutation analysis, virology, immunology and biochemistry have improved our understanding of chronic liver diseases and the possibilities for non-invasive diagnosis. "
11/01/1998 - "Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. "
11/27/1996 - "Our aim was to test its efficacy when used pre- and posttransplantation in HBV-DNA positive patients with endstage liver disease. "
07/01/1990 - "All 21 cleared the antigen during follow-up and liver disease was either mild and asymptomatic (nine cases) or clinically overt (12 cases), but none had life-threatening liver disease. "
03/01/1993 - "Blast cells with Auer rods demonstrated 8;21 translocation lacking 11q with 30 of 30 analyzed bone marrow cells, and the following antigen pattern: CD5+, CD19+, CD33+, CD56+, HLA-DR+. After 4 courses of post remission therapy, the maintenance therapy was discontinued because of his liver dysfunction. "
04/01/1988 - "In several liver diseases qualitative and quantitative changes in the HLA gene product expression can be found on hepatocytes, bile duct epithelium and sinusoidal lining cells and these changes may affect the efficacy of the immune system in recognizing an exogenous antigen. "
05/01/1985 - "We postulate that, in patients with liver disease either increased intestinal uptake resulting in increased humoral response, or decreased hepatic clearance of food antigens intensifying a humoral response to these foreign antigens, may occur."
12/01/1976 - "While persistence of the antigenaemia is associated with persisting liver disease, the converse is not true in that the disappearance of the antigen does not necessarily imply an improvement in liver disease. "
|7.||Hepatitis B Surface Antigens (HBsAg)FDA Link
05/01/1992 - "Although the frequency of HBsAg loss in treated patients is relatively low, the improvement in liver disease obtained from IFN therapy is sustained over a long period."
03/01/2014 - "It is also helpful in chronic liver disease patients where the routine HBsAg detection test is negative and the other causes of chronic liver disease have been ruled out. "
03/01/2006 - "Patients who on follow-up cleared HBsAg and/or did not develop any clinical, radiologic, or histologic evidence of chronic liver disease (CLD) were categorized as AVHB (group 1). "
10/01/2015 - "We assessed the features of female blood donors with positive serology for HBV and compared them with those of men.METHODS The study comprised consecutive blood donors referred to a specialized liver disease center to be evaluated due to HBsAg- and/or anti-HBc-positive tests. "
01/01/2014 - "The aim of this study is to evaluate the disease activity, replicative status of the virus and to find out the stages of chronic liver disease among incidentally detected asymptomatic HBsAg positive Bangladeshi subjects. "
|8.||Alanine Transaminase (SGPT)IBA
11/01/2014 - "Serum alanine aminotransferase (ALT) is important for screening, diagnosis and management of chronic liver diseases. "
01/01/2015 - "Alanine aminotransferase levels and scores on the Chronic Liver Disease Questionnaire improved to a significantly greater extent in the highest dose group (P=0.007 and P=0.021, respectively). "
08/01/1994 - "On the other hand, there was no significant rise in the level of sCD4 in patients with any liver disease, except FH, no definite relationship between sCD4 and sGPT, and no consistant tendency in sCD4 levels between exacerbation and remission. "
04/01/2010 - "SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease."
11/01/2009 - "This study presents the initial demonstration of characterizing metabolic state differences in the liver with hyperpolarized (13)C spectroscopy and shows the ability to detect physiological perturbations in alanine aminotransferase activity, which is an encouraging result for future liver disease investigations with hyperpolarized magnetic resonance technology."
|9.||Biological Markers (Surrogate Marker)IBA
06/04/2012 - "There was a significant improvement in biochemical markers of liver disease following SVR (P< 0.001). "
01/05/2010 - "Based on this pilot study we conclude: (i) high urinary epsilondA-levels, reflecting massive LPO-derived DNA damage in vivo may contribute to the development of HCC; (ii) epsilondA-measurements in urine and target tissues should thus be further explored as a putative risk marker to follow malignant progression of inflammatory liver diseases in affected patients; (iii) etheno adducts may serve as biomarkers to assess the efficacy of (chemo-)preventive and therapeutic interventions."
01/01/2009 - "The development of non-invasive biomarkers, FibroTest-ActiTest in 2001 and more recently FibroMax, as well as transient elastography (TE) has changed the management of chronic liver disease. "
04/01/1996 - "Although widely used as a serum marker, frequent false-positive results in patients with benign liver disease, result in poor specificity. "
01/01/2010 - "This study showed that 2-D DIGE-based proteomic analysis of the plasma was helpful in screening for new plasma biomarkers for liver disease. "
|10.||Interferon-alpha (Interferon Alfa)FDA Link
04/01/1996 - "Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial."
01/01/1996 - "Efficacy of human leukocyte interferon-alpha treatment in elderly patients with hepatitis-C virus-related chronic liver disease."
03/01/1994 - "Treatment with alfa-interferon (alpha IFN) was added and thereafter, the liver dysfunction improved. "
07/07/2005 - "To study the expression of interferon-alpha/beta (IFN-alpha/beta) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. "
11/01/1998 - "In addition, 120 consecutive patients with chronic liver diseases (disease control group), who had never received alpha-interferon therapy, were evaluated during the period of the study (at least for 12 months). "
04/01/2015 - "Liver transplantation is the best option for patients with severe liver dysfunction. "
07/01/2012 - "Liver transplantation, the best option for many end-stage liver diseases, is indicated in more candidates than the donor availability. "
09/01/2011 - "Liver transplantation is the best treatment for end stage liver diseases. "
06/27/2010 - "Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?"
04/27/2009 - "Liver transplantation is the best treatment option for endstage liver disease. "
|2.||Transplantation (Transplant Recipients)
01/01/2015 - "The role of SIRT regarding downstaging and bridging to transplantation is promising and SIRT has also been shown to be highly effective and well-tolerated in metastastic liver disease. "
07/01/2003 - "One year posttransplantation, follow-up data from transplant recipients showed significant improvement in most psychological domains relative to both healthy comparison participants and patients with chronic liver disease who did not undergo transplantation. "
10/01/2015 - "Hepatitis C virus viremic transplant recipients had significantly greater frequencies of biochemical chronic liver disease (P = .01). "
01/01/2015 - "This approach might be beneficial in hepatocyte transplantation for the treatment of patients with liver diseases."
11/01/2013 - "Although probiotics and even, perhaps, fecal transplantation hold promise in the management of liver disease, and the potential impact of probiotics is supported by a considerable amount of laboratory data, high-quality clinical evidence is scanty. "
08/01/2009 - "In animal models of metabolic liver disease, adopting strategies that provide a selective advantage for transplanted hepatocytes have proved to be highly effective in repopulating recipient livers, and the current relatively poor success rate of hepatocyte transplants in humans can be attributed to the lack of a clinically applicable procedure to induce a similar repopulation of the human liver. "
01/01/2009 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted hepatocytes has proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. "
12/01/2007 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted foetal or adult hepatocytes have proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. "
03/01/1996 - "Newer preservation solutions permit elective timing of the procedure and a clearer understanding of the natural history of the underlying liver disease has helped to define those patients most in need of a transplant earlier in the course of their illness. "
01/01/2014 - "In conclusion, hepatocyte transplants have proven effective particularly in cases of metabolic liver disease where reversal or amelioration of the characteristic symptoms of the disease is easily quantified. "
|4.||Drug Therapy (Chemotherapy)
02/01/2005 - "Although, severe liver dysfunction was observed, the patient achieved a complete remission (CR) on day 31 following chemotherapy and has maintained CR for more than five years. "
03/13/1998 - "Therapy with IFN-alpha for 9 weeks induced a remission in liver disease and complete remission of ML was obtained with subsequent chemotherapy. "
11/01/2013 - "Some chemotherapy is cleared by the liver and requires dose adjustment in the face of significant liver dysfunction. "
09/01/2012 - "RFA combined with chemotherapy is a promising treatment for NPC metastatic liver disease with improved local response, PFS, and OS compared to current chemotherapy protocols."
01/01/2009 - "Facial swelling and liver dysfunction improved immediately, and after five courses of chemotherapy, she achieved partial remission without any severe adverse events. "
08/01/2004 - "Since then, the management of parenteral nutrition has improved so much that nowadays adolescents have a fair chance of surviving more than 15 to 20 years without severe liver disease. "
07/01/2006 - "A randomized, controlled trial is necessary to study the efficacy of this new approach to parenteral nutrition-associated liver disease."
01/01/2015 - "Investigations on the efficacy of fish oil-based IVLEs, which are rich in n-3 PUFAs, in the treatment of parenteral nutrition-associated liver disease (PNALD) in adult patients on HPN for CIF were also analyzed. "
01/01/2010 - "She was prohibited from eating for 10 days and treated with parenteral nutrition until liver dysfunction was improved. "
09/01/2009 - "The objective was to determine the safety and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD). "